Human platelets are aggregated and induced to release their granule contents and form thromboxane by peptides as short as 6-amino acid residues (SFLLRN) corresponding to the newly released N-terminus of the thrombin receptor that is cleaved by thrombin. Using washed platelets, we found that these responses to SFLLRN (2 to 6 pmol/L) were enhanced by fibrinogen. However, neither SFLLRN nor SFL-LRNPNDKYEPF had any effect on washed rabbit or rat platelets, although they were fully responsive to human thrombin. Concentrations of the peptides as high as 100 pmol/L did not cause the platelets of rabbits or rats to change shape, aggregate, release granule contents, or form thromboxane. SFLLRN did not affect the extent of aggregation induced by adenosine diphosphate (ADP) or a low concentration of thrombin. Pig platelets responded to 50 pmol/L SFLLRN with reversible aggregation, which was HE CLONING of a thrombin receptor, and the demon-T stration that peptides corresponding to residues 42-55 (SFLLRNPNDKYEPF) or 42-47 (SFLLRN) of the thrombin receptor can activate the receptor and cause the aggregation of human platelets and the release of their granule cont e n t~, ' .~ led us to attempt to use these peptides in studies of the responses of platelets from other species. In the course of these experiments, we discovered that unlike human platelets, rabbit and rat platelets were unaffected by these peptides, and pig and guinea pig platelets were much less responsive than human platelets.
T stration that peptides corresponding to residues 42-55 (SFLLRNPNDKYEPF) or 42-47 (SFLLRN) of the thrombin receptor can activate the receptor and cause the aggregation of human platelets and the release of their granule cont e n t~, ' .~ led us to attempt to use these peptides in studies of the responses of platelets from other species. In the course of these experiments, we discovered that unlike human platelets, rabbit and rat platelets were unaffected by these peptides, and pig and guinea pig platelets were much less responsive than human platelets.
MATERIALS AND METHODS
Blood was obtained from New Zealand white rabbits, Wistar rats, and albino Hartley guinea pigs. Pig blood was obtained from a slaughterhouse. Human or rabbit platelets were isolated, labeled with I4C-serotonin (and in some experiments with "Cr), and suspended in Tyrode-albumin solution as previously described.'-'' Rabbit platelets and guinea pig platelets in citrated platelet-rich plasma (one part 3.8% trisodium citrate to nine parts ofblood) were also prepared. Suspensions of rat platelets were prepared by the method used for rabbit platelets; suspensions of pig platelets were prepared as described for human platelets, except that the osmolarity of the washing and suspending media was adjusted to 340 mOsm/L. The final suspending medium was Tyrode's solution containing 5 mmol/L HEPES, 0.35% albumin, and apyrase; platelet counts were adjusted to 500,000/pL.8 In some experiments, human fibrinogen (AB Kabi, Stockholm, Sweden) was added to the suspending medium. Shape change and aggregation were studied turbidimetrically"; 100% aggregation was defined as the difference in light transmission through a platelet suspension and the suspending medium. Release of I4C-serotonin and loss of 5'Cr were measured as described elsewhere.'.'' Thromboxane B, (TXB,) formation was assayed with radioimmunoassay kits from NEN (Lachine, Quebec, Canada). SFLLRNPNDKYEPF, a gift from Dr S.C.-T. Lam, was prepared by solid-phase synthesis in the Laboratory ofthe Research Resources Center of the University of Illinois at Chicago, IL; SFLLRN was synthesized by the Institute for Molecular Biology and Biotechnology (MOBIX) at McMaster University, Hamilton, Ontario, Canada, Human thrombin (T 6759) was from Sigma Chemical, St Louis, MO.
enhanced by fibrinogen, but not accompanied by the release of dense granule contents. Guinea pig platelets aggregated and released granule contents in response to 25 or 50 pmol/L of SFLLRN, but responded with only shape change to lower concentrations. Thus, these experiments indicate that rabbit and rat platelets lack a functional response to human thrombin receptor peptides that fully activate the previously described human thrombin receptor, despite a full response of both rabbit and rat platelets to human thrombin, and that pig and guinea pig platelets have incomplete responses to these human thrombin receptor peptides. The results suggest that platelets of rabbits and rats, and perhaps guinea pigs and pigs, respond to thrombin through an alternative receptor that has also been suggested to be present on human platelets. 
RESULTS
H u m a n platelets. As reported by other investigators,1,3,5,7 human platelets changed shape, aggregated, released dense granule contents, and formed thromboxane in response to both peptides. The presence of fibrinogen (400 pg/mL) in the suspending medium increased the aggregation response and the percentage of ''C-serotonin released from human platelets ( Fig 1A and B) ; in the presence of fibrinogen, concentrations less than 6 pmol/L SFLLRN caused maximum aggregation (Fig 1B) . There was some variation in the responsiveness of platelets from different donors. As noted by Chao et who studied human platelets in platelet-rich plasma, a small increase in the concentration of the peptide changed the aggregation response from only shape change to maximum aggregation. A similar observation was made with thrombin-induced aggregation and release of ''C-serotonin (Fig IC) . With low concentrations of SFLLRN, aggregation appeared to be reversible and the shape of the aggregation curves resembled that of primary adenosine diphosphate (ADP)-induced aggregation.I3 Loss of 5'Cr was less than 1 % in association with maximum aggregation induced by SFLLRN or thrombin, indicating Unlike the findings with human platelets, neither peptide had any apparent effect on rabbit or rat platelets in either the presence or absence of fibrinogen. In seven separate experiments, suspensions of washed platelets from rabbits did not change shape, aggregate, or release I4C-serotonin in response to 50 or 100 pmol/ L SFLLRNPNDKYEPF or 10 to 100 pmol/L SFLLRN (Fig 2A) . No formation of TXB, by rabbit platelets was detectable in response to 100 pmol/L SFLLRN. Similarly, concentrations of SFLLRN as high as 120 pmol/L had no effect on rabbit platelets in citrated platelet-rich plasma.
Rabbit and rat platelets. Suspensions of rabbit platelets aggregated and released i4C-serotonin (20 to 80%) in response to low concentrations (0.05 to 0.1 U/mL) of human thrombin (Fig 2A) . SFLLRN (100 pmol/L) did not affect the extent of aggregation, release of I4C-serotonin, or TXB, formation induced by 0.02 to 0. I U/mL of thrombin. This peptide also did not affect the extent of aggregation of rabbit platelets caused by 1 pmol/L ADP. Lysis, assessed with 5'Cr-labeled platelets, was not detectable in response to the highest concentrations of SFLLRN that were tested with suspensions of rabbit platelets.
Even in the presence of fibrinogen, rat platelets were also completely unresponsive to both peptides at concentrations ranging from 10 to 100 pmol/L. SFLLRN (75 pmol/L) caused no release of i4C-serotonin or formation of TXB,. However, rat platelets aggregated strongly (70% aggregation) in response to 0.1 or 0.2 U/mL of thrombin. Pigplatelets. The effect of SFLLRN was also tested with pig platelets. Concentrations as high as 50 pmol/L did not cause the release of I4C-serotonin, although they caused reversible aggregation; the extent of this aggregation response was increased by the presence of fibrinogen (Fig 2B) . SFL-LRN-induced aggregation occurred without a lag phase with a pattern similar to the reversible aggregation response caused by 5 or 10 pmol/L ADP in the presence of fibrinogen (results not shown). Pig platelets were responsive to human thrombin after a lag phase, although higher concentrations were required than with human, rabbit, or rat platelets (Fig  2B) .
Guinea pig platelets in citrated platelet-rich plasma aggregated in response to 25 or 50 pmol/L SFLLRN, but only shape change occurred at lower concentrations ( I O and 15 pmol/L) (Fig 2C) . Release of I4C-serotonin induced by 50 pmol/L SFLLRN averaged 44% (three experiments). The guinea pig platelets aggregated strongly to ADP and released 37% of their I4C-serotonin, indicating that secondary aggregation occurred.
Guinea pig platelets.

DISCUSSION
we found that both SFLLRN and SFLLRNPNDKYEPF caused human platelet shape change, aggregation, release of dense granule contents, and TXB, formation. Platelets from different donors vaned in their responsiveness, but maximum aggregation was achieved at concentrations of SFLLRN less than 6 pmol/L. The presence of fibrinogen in the suspending medium increased the extent of aggregation and release of ''C-serotonin, indicating that released fibrinogen was insufficient to support peptide-induced aggregation to the fullest extent. In contrast, rabbit and rat platelets did not respond in any way to the peptides in concentrations as high as 100 pmol/L. Particularly noteworthy is the absence of even a shape change response of rabbit and rat platelets with the high concentrations of the peptides, although SFLLRN at concentrations as low as 2 pmol/L caused a marked shape change of human platelets. Pig and guinea pig platelets were almost 10-fold less responsive to SFLLRN than human platelets. Thus, there are major species differences in the ability of platelets to respond to the peptides, although platelets from all the species are responsive to thrombin.
Although we are not aware that the sequences of the rabbit, rat, guinea pig, or pig platelet thrombin receptors have been studied, sequences for the thrombin receptor of human, hamster and mouse have been ~b t a i n e d . ' ,~*~,~ The regions surrounding the cleavage site of the receptor are almost identical, particularly in the domains considered to be essential for receptor activation. The peptide corresponding to SFLLRN of the human receptor is SFFLRN in the hamster and mouse. Vouret-Craviari et a16 have shown that the hamster peptide causes the release of serotonin from human platelets, and Vassallo et ai3 reported that SFALRN aggregated human platelets with the concentration required for half-maximal aggregation being 2 pmol/L, compared with
In accord with the observations of other 0.8 pmol/L for SFLLRN. Chao et al' also reported that substitution of alanine for phenylalanine in the third position of the 14-residue peptide (SFLLRNPNDKYEPF) resulted in an extent of aggregation of human platelets that was similar to that caused by SFLLRN. None of the peptides appears to have been tested in vitro with platelets from species other than human.
However, the human peptide SFLLRN has been shown to cause intravascular platelet aggregation when administered intravenously to guinea pigs.' In keeping with these findings, we observed aggregation of guinea pig platelets in vitro by SFLLRN, albeit with higher concentrations than were required with human platelets.
One would expect the rabbit and rat peptide(s) to be more similar to the hamster and mouse peptide than to the human. If the rabbit and rat peptides are the same as the hamster peptide, it seems unlikely that the Phe-Leu difference in the third position of the peptides would account for the lack of effect of high concentrations of the human peptide on rabbit and rat platelets. Nevertheless, the possibility that differences in the amino acid compositions of the peptides are responsible for our findings cannot be ruled out. Although Chao et a17 found that the region of the hamster peptide between residues 7 and 14 was detrimental to agonist activity with human platelets, our observations that high concentrations of both SFLLRNPNDKYEPF and SFLLRN were without effect on rabbit and rat platelets indicate that species differences in the peptides between residues 7 and 14 are not responsible for these observations, since SFLLRN does not contain these possibly detrimental peptides.
The lack of response of rabbit and rat platelets to high concentrations of SFLLRNPNDKYEPF and SFLLRN is surprising, since rabbit and rat platelets are fully responsive to human thrombin in the same concentration range as human platelets. Possible explanations include lack of the thrombin receptor identified by Vu et al, ' an inactivating mutation at the site where the agonist peptide binds to the receptor, the lack of, or a defect in, transmembrane signalling by the receptor, or a species difference in downstream signaling.
Coughlin et all4 have pointed out that thrombin responses that are not mimicked by the agonist peptide may be mediated by a different mechanism. They have suggested the possibility that platelets may have thrombin receptors in addition to that cloned originally by Vu et al. ' Reports by other investigators provide strong indications of the existence of at least two thrombin receptors on human platelet~."-'~ Seiler et all7 obtained evidence for two pathways of thrombin-induced activation of human platelets by examining the ability of the 14-amino acid thrombin receptor-activating peptide to desensitize platelets to thrombin; they found that platelets were desensitized to low concentrations of a-thrombin, but not to y-thrombin. This group also studied a thrombin exosite inhibitor that inhibited platelet aggregation induced by low, but not high concentrations of a-thrombin. Seiler et all7 reviewed the literature concerning two pathways, pointing out that one pathway, which they termed R, , appears to be activated by low concentrations of a-thrombin (<O. 1 U/mL) and involves a high-affinity For personal use only. on October 30, 2017. by guest www.bloodjournal.org From thrombin binding site (kd = 0.3 nmol/L). This pathway leads to activation of phospholipase A,, secretion, and inhibition of adenylate cyclase; it does not operate after chymotrypsin treatment of platelets,15 is insensitive to y-thrombin, and requires continued occupation of the thrombin receptor. 16 The other pathway of activation by thrombin, termed R, by Seiler et a]," seems to be activated by higher concentrations of a-thrombin and to be mediated by a moderate affinity binding site (kd = 10 nmol/L). They point out that it is through this pathway that thrombin activates phospholipase C and protein kinase C, and mobilizes calcium, leading to aggregation and release of granule contents. Unlike R, , this pathway is responsive to y-thrombin and continual occupation of the receptor by a-thrombin is not required.I6 Further evidence for two receptors for thrombin has been reported Bahou et al," using F(ab'), fragments of an antibody to the N-terminal 160 amino acids of the cloned thrombin receptor, found that although aggregation induced by 0.1 U/mL of thrombin was nearly abolished, a delayed shape change response persisted. Greco et all9 pointed out that the cloned thrombin receptor has characteristics similar to the moderate-affinity thrombin receptor. By blocking access to the high-affinity thrombin-binding site on glycoprotein Iba with a monoclonal antibody, they showed that both pathways are required for optimal platelet activation by a-thrombin. Gralnick et al" came to a similar conclusion from their studies with Bernard-Soulier platelets, which lack the high-affinity binding sites for thrombin and show a normal response to SFLLRN. Thus, it seems likely that activation of rabbit and rat platelets by thrombin does not involve the moderate affinity receptor cloned by Vu et al,' but probably involves the alternative receptor, or receptors.
Since high concentrations of SFLLRN neither inhibited nor potentiated the responses of rabbit platelets to human thrombin, it would appear that the peptide does not compete with thrombin for the alternative receptor that is responsible for thrombin-induced responses of rabbit platelets. In addition, SFLLRN does not have nonspecific inhibitory effects on rabbit platelets, since it did not affect ADP-induced aggregation.
The findings that rabbit and rat platelets are unresponsive to these peptides, and that pig and guinea pig platelets are almost an order of magnitude less responsive than human platelets, leads one to speculate that platelets from different species, all of which respond to thrombin, differ in the proportions of the two receptors or their characteristics. Rabbit or rat platelets may be useful for studies of the receptor that is not activated by SFLLRN.
